AI Solutions for Healthcare

March 2022 COVID-19 Updates

Background:
Two manufacturers of Covid-19 vaccines have submitted additional requests for Emergency Use Authorization (EUA) for children ages 6 months to 4 years and boosters for those fully vaccinated adults. There is a new Covid-19 test to identify mutations as well. We feel it is important to keep you abreast of the latest Covid-19 news in this ever-changing environment.  This release highlights the new codes released by the American Medical Association (AMA) and provides details of the new diagnosis codes for Covid-19 vaccine status, taking effect on April 1, 2022.

Please note the following:

    • The Food and Drug Administration (FDA) has postponed the review of the Pfizer Vaccination for children ages 6 months to 4 years until all the clinical trial data is available for review.
    • Pfizer summited a request for EUA for a booster for adults 65 or older who are at risk of severe illness from Covid-19, the FDA is currently reviewing the request.
    • The FDA authorized shortening of the time period for Pfizer boosters to five months.
    • Moderna received approval from the FDA to market its Covid-19 vaccine under the trade name of Spikevax in January of 2022.
    • Moderna also submitted a EUA request for a second booster for those over the age of 18 which the FDA is currently reviewing.
    • The AMA has published additional vaccine and administration codes pending the EUA for the boosters and new vaccines.
    • The AMA released a new CPT code (87913) to test for mutations of Covid-19 on 2-21-2022.
    • The Center for Disease Control (CDC) has released new diagnosis codes to reflect Covid-19 vaccination status.
    • Breaking news: Moderna will be submitting a request for EUA for vaccination for children ages 6 months to 6 years of age next week based on the results of their clinical trial per media reports.

Below are the Vaccination Status Diagnosis Codes Released by the CDC

Diagnosis Code Description Effective Date
Z28.311 Partial Vaccination for Covid-19 4/1/22
Z28.310 Unvaccinated for Covid-19 4/1/22
Z28.39 Other Under Immunization Status 4/1/22

 

New Test for Covid-19 Mutations

CPT Code Description Effective Date
87913 NFCT AGENT GENOTYPE ALYS NUCLEIC ACID SARSCOV2 2/21/22

 

New Vaccine and Administration Codes

Code Description  EUA Date Manufacturer Age Group Dosage
91307 Vaccine-reconstituted 10/29/21 Pfizer 5-11 Years 10 mcg/0.2 ml
0071A Admin 1st Dose 10/29/21 Pfizer 5-11 Years 10 mcg/0.2 ml
0072A Admin 2nd Dose 10/29/21 Pfizer 5-11 Years 10 mcg/0.2 ml
0073A Admin 3rd Dose 1/3/22 Pfizer 5-11 Years 10 mcg/0.2 ml
Code Description  EUA Date Manufacturer Age Group Dosage
91308 Vaccine-reconstituted Pending Pfizer 6 Mo – 4 Years 3 mcg/0.2 mL
0081A Admin 1st Dose Pending Pfizer 6 Mo – 4 Years 3 mcg/0.2 mL
0082A Admin 2nd Dose Pending Pfizer 6 Mo – 4 Years 3 mcg/0.2 mL
Code Description  EUA Date Manufacturer Age Group Dosage
91309 Vaccine Pending Moderna Over 18 50 mcg/0.5 mL
0094A Admin booster Pending Moderna Over 18 50 mcg/0.5 mL